Sanofi completed the acquisition of Ablynx for €3.9bn.

Sanofi and acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, at a price per Ablynx share of €45 in cash, which represents an aggregate equity value of approximately €3.9bn. The acquisition of Ablynx continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. “Since our founding in 2001, our team has been focused on unlocking the power of our Nanobody technology for patients. The results of our work are validated by clinical data. As we look ahead, we believe Sanofi’s global infrastructure, commitment to innovation and commercial capabilities will accelerate our ability to deliver our pipeline. Our Board of Directors feels strongly that this transaction represents compelling value for shareholders and maximizes the potential of our pipeline to the benefit of all stakeholders.” Edwin Moses, Ablynx’s Chief Executive Officer.